Dear all, please feel free to contact Elodie who will be in RDV Carnot event in Paris (Espace Champerret, 17e arrondissement) tomorrow and on Thursday. Since HCS Pharma was selected as a laureate amongst innovative start-ups and SMEs for this ecent, she will be the first to pitch at 11:40 Read more…
About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…
In this presentation, Nathalie MAUBON (CEO HCS Pharma), give an overview of drugs discovery, from pre-19th century are, where trials are done on humans, to nowadays where clinical trials are safer but with a dramatic rate of failure. She explains what are the “target base screening” and the “phenotypic screening Read more…
From different studies we know that more than 92% of drug candidates for Central Nervous System diseases fail in clinical trials, with 34% of safety failure. All that candidates have successfully passed in vitro steps and animal testing. Conclusion is straightforward : we have to deeply change biological models in Read more…
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the gap between in vivo and in vitro situations by taking into account the extracellular matrix Read more…
Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in vitro, qui ne prennent pas en compte le microenvironnement, composé par les cellules gliales et Read more…
Présentation en français About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix Read more…
When Tuesday, October 4, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, October 6, 2022 – 1:30PM (CEST) / 7:30PM (CST) / 8:30PM (JST) / 7:30AM (EST) Where Online, using zoom.us and live on Youtube What About 90% of drug candidates fail in clinical Read more…
Next month, we will have the pleasure to participate in the 23rd EUSAAT (EUropean Society for Alternative to Animal Testing) congress, which will take place in Linz (Austria) on the 26th-28th of September. We have proposed an abstract about how we use 3D in vitro cell culture models for recapitulating Read more…
There are several products today for 3D cell culture and many could be considered as “hydrogels”. In this short article, we explain differences between BIOMIMESYS® and hydrogels to help you to choose the right product for your very specific needs. In 3D cell cultures, many hydrogels could be used like Read more…
The Federation of European Neuroscience Societies (FENS) forum 2022 took place in Paris, from 9 to 15 July. This event gathers nearly 8,000 neuroscientists from 92 countries. Twenty-two plenary and special lectures were given in 8 conferences room, about various topics in neurosciences, like brain imaging methods, brain development (synapse Read more…
Alejandra is a pharmacist graduated from University Católica de Santa María, Arequipa – Peru. She obtained her PhD in Biomolecules, pharmacology and therapeutics at the University of Lille in 2018. During her doctoral formation, Alejandra worked with biomaterials in the development of a wound dressing providing a dual therapy for Read more…
We are very pleased to talk with Pr Robert-Alain Toillon from University of Lille about his uses of BIOMIMESYS® technology in oncology and more specificaly on breast cancer. English is below Je m’appelle Robert-Alain Toillon je travaille au laboratoire Canther dans l’institut OncoLille sur le cancer du sein et plus Read more…
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…
Aim: About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix (ECM). The Read more…
Our project leader in in vitro pharmacology Veronique De Conto will be present to the Federation of European Neurosciences Societies (FENS) congress, from 9 to 13 July in Paris. She will present a poster about the importance of microenvironment in cerebral in vitro models for phenotypic screening, in the frame Read more…
Elodie Vandenhaute (our project director), Véronique De Conto (our project leader in in vitro pharmacology) and Natacha Perrin (our trainee in neurosciences) were present at the annual SCMC (Société Cerveau et Maladies Cérébrovasculaires – The French Brain and Cerebrovascular Diseases Society) congress, which took place on the 16th of June Read more…
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation, progression, and propagation, and also impact the responses of cancerous cells to treatments. Read more…
3D cell culture systems have recently emerged as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). In this webinar we will focus on BIOMIMESYS® Liver and will discuss about its different applications. Read more…
When Tuesday, June 28, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, June 30, 2022 – 1PM (CEST) / 7PM (CST) / 8PM (JST) / 7AM (EST) Where Online, using zoom.us and live on Youtube What Solid tumors are associated with a modified microenvironment, Read more…
